PRC vaccine maker offers follow-on

    | BY

    clpstaff &clp articles

    Sinovac Biotech, a China-based manufacturer of vaccines has completed a US$66 million follow-on public offering. The company offered 11.5 million common…

    Sinovac Biotech, a China-based manufacturer of vaccines has completed a US$66 million follow-on public offering. The company offered 11.5 million common shares, including 1.5 million common shares sold when the underwriters, UBS and Piper Jaffray, exercised their over-allotment option in full.

    O'Melveny & Myers acted for the underwriters with Beijing partner David Roberts leading a team that included Bejing partners Nate Bush and Larry Sussman, and Shanghai partner Kurt Berney. Lathan & Watkins, Haiwen & Partners and East Associates Law Firm represented Sinovac.

    This premium content is reserved for
    China Law & Practice Subscribers.

    • A database of over 3,000 essential documents including key PRC legislation translated into English
    • A choice of newsletters to alert you to changes affecting your business including sector specific updates
    • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
    For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]